MYDENTALWIG™: AN INTEGRATED TECHNOLOGY ECOSYSTEM

From the mouth to intelligence.

MYDENTALWIG is building a vertically integrated technology ecosystem connecting dental innovation, human health, EI (Extraordinary Intelligence), sensing, advanced manufacturing, and intelligent infrastructure — one continuous system, from the smile to the data center.

Please read “EI” – Extraordinary Intelligence – wherever “AI” appears in this website.

“Prevention Is Better Than Cure.”

OFFERING MATRICES: REGULATION D, RULE 506(c) GENERAL SOLICITATION

MYDENTALWIG™, INC. — INSTITUTIONAL CAPITAL ADMISSION PORTAL

Initial Financing Tranche
$21,000,000 OPEN
Investment Instrument
SAFE (Simple Agreement for Future Equity)
Fixed Valuation Cap
$1,000,000,000
Target Vertical
DentalWig PLUS™ — Diabetes (Metabolic Intelligence Platform)

THE TRANCHE 1 VALUE-CREATION MANDATE

This initial $21,000,000 ($21 Million usd) financing round is structured as a defined 12-month value-creation and de-risking program. Proceeds are strictly allocated to move our patented intraoral ingestion-sensing technology from its current pre-commercial validation phase into active revenue generation and human clinical pilot tracking.

MYDENTALWIG’s First EI² ™ (Extraordinary Ingestion Intelligence™) Powered Product:

DentalWig PLUS™ ─ Diabetes

PATENT INFORMATION

Re: TRANSMITTAL OF FINAL APPLICATION AS FILED
TITLE: ARTIFICIAL-INTELLIGENCE-DRIVEN INTRAORAL INGESTION-SENSING AND METABOLIC-GUIDANCE SYSTEM
APPLICATION SERIAL NUMBER: 19752971
ATTORNEY DOCKET NO.: 1610-05UA

Dear Lydie,

I am happy to report that the above-described Utility patent application was filed July 24th, 2026.

Patent Attorney: Eric Karich

This is a time-critical opportunity for American innovation. U.S. government investment or grant support for MYDENTALWIG would provide the financial capacity to meet the international patent deadline and secure worldwide protection for this U.S.-developed invention. Our 12-month DentalWig PLUS™ roadmap is already in place, and with timely funding, we can move from roadmap to execution and make our proprietary chip available—strengthening American leadership in this emerging technology.

CURRENT DEVELOPMENT STAGE

MYDENTALWIG is a patent-stage health technology company developing DentalWig PLUS™ — Diabetes, an EI²™ (Extraordinary Ingestion Intelligence)-powered ingestion-intelligence platform designed to capture objective eating behavior and correlate ingestion events with continuous metabolic data, with the end-goal to prevent illnesses.

The company is currently at the pre-commercial validation stage. The core investment opportunity is not based on an assumption that every technical and clinical hypothesis has already been proven. Rather, the 12-month development program is designed to systematically validate the critical technical, scientific, clinical, regulatory and commercial assumptions required to commercialize the platform.

The $21 million financing is intended to fund this de-risking and value-creation program—not merely to fund an idea.

Patented Ingestive Intelligence™:

DCI ─ Dental Computing Interface™ for Metabolic Disease Prevention

MYDENTALWIG’s 1st EI² ™ Powered Product:

DentalWig PLUS™ ─ Diabetes

1. We measure what people eat and predict how their body responds before disease begins.

2. PROBLEM

The diabetes crisis is behavioral + invisible

1 in 3 adults has prediabetes

Most people:

Core gap in medicine:

We cannot reliably measure what people actually eat in real time

Result:

3. WHY CURRENT SOLUTIONS FAIL

Wearables (Apple Watch, Fitbit)

CGMs (Dexcom, Libre)

Continuous Glucose Monitor (CGM)

Food logging apps

4. CLINICAL VALIDATION & PEER-REVIEW PIPELINE STATUS

To ensure highest-level corporate governance, scientific transparency, and long-term asset defensibility, MYDENTALWIG™ maintains an active publication track within premier peer-reviewed scientific journals and medical societies.

Our core technological manuscript—detailing the micro-sensor methodology, edge-AI algorithms, and the integration of objective intraoral ingestion-sensing nodes with downstream continuous glucose monitor (CGM) metrics—is tracking through the following institutional pipelines:

CURRENT EDITORIAL STATUS DEPLOYMENT MATRIX:

AMERICAN DIABETES ASSOCIATION (ADA)

Formal pre-submission technology framework brief cleared initial administrative processing and is officially under active consideration by the ADA Peer Review and Editorial Production teams.

AMERICAN DENTAL ASSOCIATION (JADA)

Submission architecture is finalized. Full methodology manuscript routing is scheduled for deployment immediately following the ADA’s November 15, 2026 centralized online portal transition.

This parallel academic deployment de-risks incoming Regulation D, Rule 506(c) private equity tranches. By validating our underlying U.S. Utility Patent Application (Serial No. 19752971) within top-tier clinical metabolism and dental registries, we convert our patent-stage innovations into an internationally recognized, scientifically backed digital health infrastructure asset.

5. INSIGHT (BIG IDEA)

Metabolic disease is caused by ingestion behavior + physiological response mismatch — and we only measure half the system.

Missing piece:

real-time ingestion intelligence

6. SOLUTION

6. SOLUTION:

🦷 MYDENTALWIG is developing an Ingestion Intelligence™ Platform designed to capture objective ingestion behavior and connect it with physiological response, measuring what people eat and predicting how their body responds before disease begins.

A system that captures:

7. PRODUCT

Phase 1 (MVP): EI-Powered & Hybrid-Charging Smart Dental Device (EI²) + App

Dental ingestion sensor

Mobile app

CGM integration

8. HOW IT WORKS

1

User eats → device detects ingestion event

2

Wearable captures context (sleep, stress, activity)

3

CGM records glucose response

4

EI learns personalized metabolic response curve

5

System provides real-time guidance:

“This meal will spike glucose above safe range — reduce portion or adjust timing.”

9. TECHNOLOGY

Core EI stack:

Edge + cloud architecture:

10. WHY NOW

10. WHY NOW

Three converging trends:

Enabling technologies:

11. TAM

11. TAM Market Valued ─: $31.5+ Trillion

Initial focus:

Expansion:

12. BUSINESS MODEL

B2C:

B2B:

13. COMPETITIVE ADVANTAGE

We own what others cannot measure:

Company typeWhat they measure
Wearablesphysiology
CGM companiesglucose
Food appsself-report
Wereal ingestion behavior

14. DEFENSIBILITY

Potential Data Moat

Every validated ingestion event can become part of a longitudinal dataset linking eating behavior, timing, behavioral patterns and physiological response. As the dataset grows, it may improve personalization, model performance and prediction capabilities, potentially creating increasing barriers to entry.

15. TRACTION PLAN (V1 → V2) - 12-MONTH VALIDATION ROADMAP

Phase 1 — Technical Feasibility

Objective: Determine whether intraoral sensing can reliably detect and characterize ingestion events.
Deliverables:
Value created: Establishes technical feasibility and reduces core technology risk.

Phase 2 — Human Pilot

Objective: Validate performance under real-world eating conditions.
Value created: Converts laboratory feasibility into human evidence.

Phase 3 — Metabolic Intelligence

Objective: Determine whether objective ingestion data improves metabolic prediction.
Value created: Establishes the scientific foundation for the EI²™ platform.

Phase 4 — Intervention

Objective: Determine whether real-time ingestion intelligence can influence behavior.
Value created: Establishes potential clinical and commercial utility.

Phase 5 — Commercialization

16- WHAT INVESTORS ARE FUNDING

Investors are not being asked to fund an unbounded research project. The $21 million financing is intended to fund a defined 12-month program with identifiable technical, clinical, regulatory, manufacturing and commercial milestones.

The capital is intended to produce:

Accordingly, the investment opportunity is based not solely on the present concept, but on the enterprise, value expected to be created through successful execution of these measurable milestones.

17. REGULATORY STRATEGY

18. TEAM

19. VISION

We are building the missing sensory layer of human metabolism — turning eating behavior into measurable, learnable biology.

Long-Term Vision

The missing sensory layer of human metabolism.

12-Month Objective

Demonstrate that intraoral sensing can reliably generate clinically useful ingestion intelligence and establish the technical foundation for commercialization.

Current Healthcare

Disease → Symptoms → Diagnosis → Treatment

MYDENTALWIG

Food Ingestion → Continuous Physiological Intelligence (CPI) → Prediction → Prevention

An ingestion-centric computational model of human physiological state, resilience, and health trajectory.

20- FROM PATENTED TECHNOLOGY TO VALIDATED, REVENUE-GENERATING PLATFORM

MYDENTALWIG is not being presented as an idea accompanied by a roadmap. The Company has established a patented technology thesis, defined its technology architecture, identified the critical technical and clinical assumptions that must be validated, and developed a structured 12-month program to move those assumptions through measurable stages of validation and commercialization.

The Company’s value-creation pathway is:

PATENTED TECHNOLOGY THESIS
↓
TECHNICAL VALIDATION
↓
HUMAN VALIDATION
↓
METABOLIC / CLINICAL VALIDATION
↓
COMMERCIAL PRODUCT
↓
COMMERCIAL VALIDATION
↓
RECURRING REVENUE
↓
PLATFORM SCALE

The proposed $21 million financing is designed to fund this transition—from patented technology and pre-commercial development through technical and human validation, clinical development, product commercialization, initial recurring revenue and the creation of a scalable EI-driven healthcare platform.

Accordingly, the investment thesis is not based solely on the present concept. It is based on the Company’s ability to deploy capital against a defined sequence of technology validation, value-creation and commercialization milestones, with each successful stage intended to reduce risk and increase enterprise value.

20- MYDENTALWIG'S $21 MILLION FINANCING

20- MYDENTALWIG'S $21 MILLION FINANCING VALUE-CREATION

MYDENTALWIG is not presenting the $21 million financing as capital required simply to pursue an idea. The financing is designed to fund a defined 12-month program encompassing technology development, AI development, sensor engineering, human pilot studies, CGM-integrated validation, clinical development, regulatory preparation, manufacturing infrastructure, commercialization and the creation of proprietary ingestion-intelligence data.

The investment thesis is therefore based on the transformation of MYDENTALWIG from a patent-stage, pre-revenue technology company into a validated, commercially deployable EI-driven healthcare platform with intellectual property, proprietary data, recurring subscription revenue and multiple future applications.

Capital Deployment

Infrastructure

Product Development

Artificial Intelligence

Clinical Validation

Regulatory

Commercialization

Value Creation Milestones

This investment is expected to unlock:

Revenue Model

B2C: EI²™ Dentalwig ─ Diabetes

B2B: EI²™ Pro ─ Diabetes by Dentists

Embedded EI²™ sensor technology licensed to dental professionals for:

Additional subscription revenue from:

Investment Outcome

The proceeds are intended to transition MYDENTALWIG from a pre-revenue innovation company into a recurring revenue EI healthcare platform with multiple revenue streams, significantly increasing enterprise value through commercial traction, proprietary data assets, intellectual property expansion, and scalable subscription-based recurring revenue.

22. ASK

Reg D 506 (c)

for verified accredited investors only through 3rd party. Minimum investment: $1,000,000 usd

Reg CF

for accredited and non-accredited investors verified by 3rd party. Minimum investment: $1,000 usd up to $5,000,000 usd.

$21 M initial (as a reminder, OpenAI received $38 M initial funding)

How does investing $21 million today create a company that will be worth substantially more tomorrow: by unlocking specific value-creating milestones that significantly reduce risk and increase the company’s valuation.

WHY $21 MILLION?

The $21 million financing is structured as a value-creation and risk-reduction program.

The objective is to transform MYDENTALWIG through identifiable development stages:

Patent-stage technology
↓
Technical feasibility
↓
Human validation
↓
Clinical/metabolic evidence
↓
Commercial product
↓
Revenue
↓
Proprietary data asset
↓
Scalable EI healthcare platform

The investment thesis is not that the company has already eliminated technical and clinical risk. The investment thesis is that capital is deployed to eliminate defined categories of risk while simultaneously creating intellectual property, proprietary data, validated technology, commercial infrastructure and recurring revenue.

Risk-reduction architecture

Today$21M programResult
Patent filedEngineering + prototype validationTechnical feasibility
Hypothesis50–200 user pilotHuman data
Conceptual EICGM paired datasetValidated algorithms
Prototype-stageManufacturing developmentScalable product
Pre-revenueCommercial launchRevenue
No proprietary datasetLongitudinal ingestion datasetData moat
Unvalidated predictionClinical evidenceReduced scientific risk

CAPITAL REQUIREMENTS FOR TRANSFORMATIVE TECHNOLOGY

Significant capital can be committed to transformative technologies before the ultimate commercial product, market scale, or economic outcome has been fully established.

For example,

These examples demonstrate an important principle: transformative technology investment is not necessarily limited to companies that have already completed product development, achieved profitability, or eliminated technical uncertainty. Investors provide substantial capital when they believe the underlying technological opportunity is significant and when the capital can be deployed against a defined plan capable of creating substantial additional enterprise value.

23- SOURCE & USE OF FUNDS SUMMARY

Sources of FundsAmount (USD)
Reg D Rule 506(c) Offering$21,000,000
Total Sources of Funds$21,000,000
Source & Uses of FundsAmount (USD)% of Total
Research, Development & Pilot Manufacturing Infrastructure (facility build-out, laboratories, pilot manufacturing equipment, EI infrastructure)$7,745,00036.9%
Personnel & Operations (engineering, manufacturing, EI, administration, facility operations, benefits)$4,250,00020.2%
Product Development & Clinical Validation$3,500,00016.7%
Regulatory, Intellectual Property & Professional Services$2,250,00010.7%
Sales, Strategic Partnerships & Business Development$1,250,0006.0%
Working Capital & Contingency Reserve$2,005,0009.5%
Total Uses of Funds$21,000,000100.0%

24. MYDENTALWIG – OFFERING TERMS SUMMARY

CATEGORYDETAILS
Offering TypeRule 506(c) Private Placement (Reg D exemption)
Minimum Investment$1,000,000 per investor at $1 billion Pre-money Valuation (Current Reg CF terms)
Accredited Investor– Individual net worth > $1M (excluding primary residence), or annual income > $200k (or $300k with spouse) in the last 2 years, expecting consistency in current year
– Entities such as $5M+ asset corporations, trusts, or Qualified Purchaser categories
– Other qualifying categories include Series 7/65/82 holders or entity owners composed solely of accredited investors
Verification ProcessUsing third-party accredited verification service
Security OfferedSAFE Preferred Stocks
Form D FilingSEC Form D to be filed within 15 days of first sale, with updates 30 days post final sale if extending
Closing TimelineThe offering will remain open until a closing is determined by the Company, based on investor commitments and subject to applicable regulatory requirements. No specific closing date has been established. Funds will be held in the Company’s bank account until closing.
Offering ExpirationThe offering will remain open until such time as the Company determines to terminate or close the offering, subject to applicable securities laws and regulations.
Use Of Proceeds• Construction of 8 million SF giga factory that includes IDM, AI, production lines, QC/QA, Smile Engineering Academy (SEA) etc. areas.
• LYDIE TOWER, Housing, 2GU Davinci Resort & smart-city infrastructure
• CapEx, R&D, marketing, and working capital
Transfer RestrictionsSecurities are restricted and may not be resold unless registered under the Securities Act or an exemption is available; generally subject to a 6-month holding period under Rule 144
Bad Actor DisqualificationThe offering is subject to “bad actor” disqualification provisions; any involvement by disqualified persons will bar use of Reg D exemption

24. INVESTOR QUALIFICATION

Investor Qualification & Compliance Layer

MANDATORY VERIFICATION PROTOCOL FOR PRIVATE REGULATION D INQUIRIES

To ensure absolute operational efficiency and maintain strict adherence to SEC Rule 506(c) compliance, our executive desk operates a zero-broker friction policy. We only review, process, and respond to direct communications from institutional entities or individual principal partners who strictly fulfill the following regulatory thresholds and verification steps:

VERIFIED ACCREDITED INVESTOR STATUS:

The inquiring party must fulfill the statutory definition of an Accredited Investor under SEC Rule 506(c) / Rule 501 parameters:

INSTITUTIONAL MINIMUM ALLOCATION:

Because our structured initial tranche maintains a strict $1,000,000 ─ $1 million USD minimum investment requirement per investor, you must ensure your fund allocation models legally permit a minimum check size of this magnitude.

DIRECT THIRD-PARTY VERIFICATION PROTOCOL:

To protect privacy and automate compliance, MYDENTALWIG™ does not accept unverified financial documents directly. Investors must complete their verification through our official third-party compliance portal. Clicking the link below routes you directly to our dedicated setup, skipping all manual site navigation:

DIRECT SUBSCRIPTION SUBMISSION:

Once your background check is successfully completed, your attorney-certified Accreditation Verification Letter (PDF Format) will be generated. Qualified principals must email this final verification certificate alongside their technical due-diligence questions directly to our placement desk:

👉 Executive Desk Contact: invest@mydentalwig.com

All non-compliant, unverified, or intermediate broker-dealer solicitations are programmatically filtered out. We will promptly respond to all inquiries matching these corporate standards.

25. CONTACT

MYDENTALWIG is a privately capitalized advanced manufacturing platform developing a $200 billion vertically integrated industrial ecosystem known as Sainte Lydie City, designed to reshore strategic production to the United States. Through AI-integrated manufacturing, semiconductor-enabled health technologies, renewable energy generation, and workforce development infrastructure, the company is building a next-generation model for resilient, high-value American industry.

INVEST

Investing in
what comes next.

MYDENTALWIG began with a patented, FDA-cleared dental device and a fundamentally different approach to replacing missing teeth.

Today, we are building beyond the device — developing proprietary sensing and EI technologies designed to transform the mouth into an intelligent interface and connect continuous ingestion data with personalized health intelligence.

Our long-term vision is a vertically integrated, closed-loop ecosystem connecting human health, EI, research, advanced manufacturing and intelligent infrastructure.

A foundation already built.
A much larger opportunity ahead.

PROVEN FOUNDATION

What already exists

TECHNOLOGY PLATFORM

What we are building

LONG-TERM OPPORTUNITY

Where it can go

WHY NOW?

A convergence that makes this possible.

The convergence of EI, sensing, advanced manufacturing and personalized health is creating an opportunity to rethink how healthcare data is generated and used.

MYDENTALWIG is approaching that opportunity from an unconventional starting point: the mouth.

The place where we eat, drink, bite, chew and interact with the substances that enter our bodies every day.

THE INVESTMENT OPPORTUNITY

A company at the intersection of six domains.

Dental technology×Sensing×EI×Health intelligence×Advanced manufacturing×Infrastructure

… with the objective of creating a closed-loop technology ecosystem that can expand far beyond the original dental device.

We’re building the infrastructure for a different kind of healthcare intelligence.

INVEST

We’re building the next generation of health technology from an unexpected place: the mouth.

THE STORY IN ONE LINE
We exist
A real company with history.
We built
A patented, FDA-cleared device.
People bought
Real customers, real experiences.
We expanded
Education, research, manufacturing.
We invented
DCI™ and EI²™.
We are building
The platform and the ecosystem.
Here’s where it can go
A closed-loop health intelligence system.